Pre-earnings options volume in Iovance Biotherapeutics (IOVA) is 2.2x normal with calls leading puts 8:7. Implied volatility suggests the market is anticipating a move near 12.4%, or 67c ...

Iovance Biotherapeutics recently reaffirmed its earnings guidance for 2025 and projected significant revenue growth for 2026, alongside announcing a notable revenue increase in its 2024 earnings ...

Feb. 27, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor ...